TY - JOUR
T1 - Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men
AU - Pavlou, Spyros N.
AU - Wakefield, Gail B.
AU - Island, Donald P.
AU - Hoffman, Philip G.
AU - Lepage, Mary E.
AU - Chan, Rebecca L.
AU - Nerenberg, Clinton A.
AU - Kovacs, William J.
PY - 1987/5
Y1 - 1987/5
N2 - LHRH antagonists compete with endogenous LHRH for binding to receptors on pituitary gonadotrophs and thereby inhibit gonadal function by suppressing gonadotropin secretion. Westudied the effects of a recently developed LHRH antagonist on the pituitary-gonadal axis in man. The antagonist Detirelix ([N-Ac-D-Nal(2)1) D-pCl-Phe2)D-Trp3, D-hArg(Et2)6, D-Ala10] LHRH) was given as a single sc injection to nine normal men at three dose levels (5, 10, and 20mg) at intervals of at least 7 days. Serum FSH, LH, and testosterone levels were measured before treatment, at frequent intervals for 48 h, and 72, 96, and 168 h after administration of the antagonist. Mean serum FSH levels decreased (P < 0.001) from 6.9 ± 0.5 (±SEM) mlU/mL to nadirs of 4.4 ± 1.1, 3.6 ± 0.9, and 4.1 ± 0.9 after the 5-, 10-, and 20-mg doses, respectively. Serum LH levels decreased (P < 0.001) from 6.2 ± 0.3 mlU/mL to nadirs of 3.3 ± 0.4, 2.8 ± 0.3, and 2.7 ± 0.3 after all three doses. Serumtestosterone levels decreased (P < 0.001) in a dose-dependent fashion from 5.1 ± 0.2 ng/mL to nadirs of 1.3 ± 0.3, 0.9 ± 0.3, and 0.6 ±0.1 after the same doses. After the initial testosterone decrease, however, escape occurred 12-28 h after the lower doses. The area under the response curve, describing hormone concentrations as a function of time during the study, diminished by 23 ± 2%, 36 ± 4%, and 36 ± 3% for FSH, by 14 ± 6%, 30 ± 6%, and 34 ± 5% for LH, and by 41 ± 5%, 58 ± 6%, and 68 ± 4% for testosterone with the same doses, respectively. The apparent plasma disappearance half-life of Detirelix by RIA was at least 41 h after all three doses. Detirelix elicited only a minor local reaction; no systemic side-effects were observed within the dose range used. These results indicate that this LHRH antagonist is a safe, highly potent inhibitor of the human pituitary-gonadal axis with an exceptionally long duration of action.
AB - LHRH antagonists compete with endogenous LHRH for binding to receptors on pituitary gonadotrophs and thereby inhibit gonadal function by suppressing gonadotropin secretion. Westudied the effects of a recently developed LHRH antagonist on the pituitary-gonadal axis in man. The antagonist Detirelix ([N-Ac-D-Nal(2)1) D-pCl-Phe2)D-Trp3, D-hArg(Et2)6, D-Ala10] LHRH) was given as a single sc injection to nine normal men at three dose levels (5, 10, and 20mg) at intervals of at least 7 days. Serum FSH, LH, and testosterone levels were measured before treatment, at frequent intervals for 48 h, and 72, 96, and 168 h after administration of the antagonist. Mean serum FSH levels decreased (P < 0.001) from 6.9 ± 0.5 (±SEM) mlU/mL to nadirs of 4.4 ± 1.1, 3.6 ± 0.9, and 4.1 ± 0.9 after the 5-, 10-, and 20-mg doses, respectively. Serum LH levels decreased (P < 0.001) from 6.2 ± 0.3 mlU/mL to nadirs of 3.3 ± 0.4, 2.8 ± 0.3, and 2.7 ± 0.3 after all three doses. Serumtestosterone levels decreased (P < 0.001) in a dose-dependent fashion from 5.1 ± 0.2 ng/mL to nadirs of 1.3 ± 0.3, 0.9 ± 0.3, and 0.6 ±0.1 after the same doses. After the initial testosterone decrease, however, escape occurred 12-28 h after the lower doses. The area under the response curve, describing hormone concentrations as a function of time during the study, diminished by 23 ± 2%, 36 ± 4%, and 36 ± 3% for FSH, by 14 ± 6%, 30 ± 6%, and 34 ± 5% for LH, and by 41 ± 5%, 58 ± 6%, and 68 ± 4% for testosterone with the same doses, respectively. The apparent plasma disappearance half-life of Detirelix by RIA was at least 41 h after all three doses. Detirelix elicited only a minor local reaction; no systemic side-effects were observed within the dose range used. These results indicate that this LHRH antagonist is a safe, highly potent inhibitor of the human pituitary-gonadal axis with an exceptionally long duration of action.
UR - http://www.scopus.com/inward/record.url?scp=0023220683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023220683&partnerID=8YFLogxK
U2 - 10.1210/jcem-64-5-931
DO - 10.1210/jcem-64-5-931
M3 - Article
C2 - 3104388
AN - SCOPUS:0023220683
VL - 64
SP - 931
EP - 936
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 5
ER -